The Rac1 pathway is a key player in cancer cell growth, movement, and survival. As a small GTPase in the Rho family, Rac1 acts like a switch, controlling how cancer cells spread and resist treatment. Due to its impact on tumor progression, Rac1 is being explored as a promising target for new cancer therapies.​​

​

Utilizing AI-driven phenotyping and drug screening, we have successfully identified and patented 30 distinct small-molecule drugs for further evaluation against various cancer cell lines. The XTL-152 series is currently being investigated for its potential to treat malignancies within the GTP binding domain. Specifically, the XTL-152 compound focuses on inhibiting the Rac1 pathway, providing a promising treatment approach for cancers such as glioblastoma, paving the way for innovative cancer treatments.